Stability of full-length recombinant FVIII formulated with sucrose during continuous infusion using a mini-pump infusion device [1]

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 7, 2005, Pages 1530-1531

  Henze, W ^a   Kellermann, E ^b   Larson, P ^c   Gorina, Eduard ^c  

^a B   (Germany)

^b BAYER AG   (Germany)

^c BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8; SUCROSE; F8 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

BLOOD CLOTTING DISORDER; CLINICAL TRIAL; HEMOPHILIA A; HUMAN; INFUSION PUMP; INFUSION SYSTEM; LETTER; META ANALYSIS; PLASMA FACTOR; PRIORITY JOURNAL; SYSTEMATIC REVIEW; CHEMISTRY; DRUG EFFECT; HEMOSTASIS; INTRAVENOUS DRUG ADMINISTRATION; REPRODUCIBILITY; TIME;

FACTOR VIII; HEMOSTASIS; HUMANS; INFUSION PUMPS; INFUSIONS, INTRAVENOUS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SUCROSE; TIME FACTORS;

EID: 25144474568     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01400.x     Document Type: Letter

References (4)

1. Abshire T, Brackmann H-H, Scharrer I, Hoots K, Gazengel C, Powell JS, Gorina E, Kellermann E, Vosburgh E, the International Kogenate-FS Study Group. Sucrose-formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy: results of a multicenter, international, clinical investigation. Thromb Haemost 2000; 83: 811-16.
2. Schulman S. Continuous infusion. Haemophilia 2003; 9: 368-75.
3. Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. Br J Haematol 2000; 110: 715-20.
4. Hurst D, Zabor S, Malianni D, Miller D. Evaluation of recombinant factor VIII (Kogenate) stability for continuous infusion using a mini-pump infusion device. Haemophilia 1998; 4: 785-9.